<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04103190</url>
  </required_header>
  <id_info>
    <org_study_id>ALR_2019_4</org_study_id>
    <nct_id>NCT04103190</nct_id>
  </id_info>
  <brief_title>Multiparametric Imaging for Analysis of MVNT (Multinodular and Vacuolating Neuronal Tumor)</brief_title>
  <acronym>MIAM</acronym>
  <official_title>Multiparametric Imaging for Analysis of MVNT (Multinodular and Vacuolating Neuronal Tumor)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Differential diagnoses of MVNT include DNT (dysembryoplastic neuroepithelial tumor),
      low-grade gliomas, cortical dysplasias or even hamartomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Differential diagnoses of MVNT include DNT (dysembryoplastic neuroepithelial tumor),
      low-grade gliomas, cortical dysplasias or even hamartomas.

      However, in order to avoid an invasive surgical procedure to remove the lesion, a certain
      diagnosis of its benignity is essential. The contribution of advanced techniques in MRI, such
      as spectroscopy in the characterization of these lesions, has not yet been studied today
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Description of a new radiological entity on Spectroscopy : the MVNT (Multinodular and Vacuolating Neuronal Tumor)</measure>
    <time_frame>1 day</time_frame>
    <description>ratio of N-Acetylaspartate / Choline on Spectroscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of a new radiological entity on Spectroscopy : the MVNT (Multinodular and Vacuolating Neuronal Tumor)</measure>
    <time_frame>1 day</time_frame>
    <description>area under curve of the N-Acetylaspartate Spectroscopie</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of a new radiological entity on Spectroscopy : : the MVNT (Multinodular and Vacuolating Neuronal Tumor)</measure>
    <time_frame>1 day</time_frame>
    <description>area under curve of choline Spectroscopie</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Benign Neuronal Desease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>cerebral MRI</intervention_name>
    <description>Patients who agree to participate in the study will perform a 3T multi-parametric MRI with advanced spectroscopic imaging techniques and standard protocol.
A neurological consultation will take place during the inclusion visit as well as a questionnaire and a control MRI at 1 year and 2 years +/- 1 month.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient supported for suspicion of MVNT
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over 18 years old

          -  Suspicion of MVNT on an MRI: it is considered that it will be necessary at least the 2
             major criteria associated with at least 1 minor criterion to enter the definition of
             suspicion of MVNT:

        Major criteria:

          -  Multinodular aspect in cluster

          -  High FLAIR hypersignal / T2

        Minor criteria:

          -  Absence of mass effect

          -  Hyposignal T1

          -  Center of the lesion in hypsignal FLAIR or T1 hypersignal

               -  Affiliate or beneficiary of a Social Security scheme

               -  Having received informed information about the study and consenting to
                  participate in the study

        Exclusion Criteria:

          -  Patient benefiting from a legal protection measure

          -  Pregnant or lactating woman

          -  Contraindication to MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laurence Salomon, MD PhD</last_name>
    <phone>0148036431</phone>
    <phone_ext>+33</phone_ext>
    <email>lsalomon@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Augustin Lecler, MD PhD</last_name>
    <phone>0418036401</phone>
    <email>alecler@for.paris</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Groupe Hospitalier Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Touridas, MD PhD</last_name>
      <email>thomas.tourdias@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondation Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Augustin Lecler, PhD</last_name>
      <email>alecler@for.paris</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François Cotton, MD PhD</last_name>
      <email>francois.cotton@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Béatrice Carsin-Nicol, MD PhD</last_name>
      <email>Beatrice.CARSIN.NICOL@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanue Gerardin, MD PhD</last_name>
      <email>Emmanuel.Gerardin@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Laennec</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesus AGUILLAR, MD PhD</last_name>
      <email>elisabeth.calvier@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pierre Paul Riquet, CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrice BONNEVILLE, MD PhD</last_name>
      <email>bonneville.f@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 21, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

